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Atorvastatin Decreases Cellular Proliferation and
Bone Matrix Expression in the Hypercholesterolemic Mitral Valve
To the Editor: Idiopathic calcification of the mitral annulus is one
of the most common cardiac abnormalities demonstrated at
autopsy (1). Currently, the pathophysiology of mitral annular
calcification (MAC) is viewed as a passive degenerative process due
to a buildup of calcium along the mitral valve leaflet and annulus.
Recent epidemiologic studies have defined the risk factors for the
development of MAC, which include hypertension, hypercholes-
terolemia, smoking, and male gender (2–4). These reports also
have examined the association between mitral valve calcification
and atherosclerosis; however, few experimental models have dem-
onstrated these changes. Atherosclerosis is established as an active,
cellular process within the vessel wall activated by an inflammatory
Figure 1. Light microscopy of rabbit mitral valves and papillary muscle. Left column  control diet; middle column  cholesterol diet with the arrow
pointing to the valve leaflet; right column  cholesterol diet plus atorvastatin. (All frames: magnification, 12.) (A) Alpha-actin immunostain. (B)
RAM-11, macrophage immunostain. (C) Proliferating cell nuclear antigen (PCNA) immunostain. (D) Masson trichrome stain. (E) Osteopontin
immunostain.
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mechanism (5). The mitral annulus and aortic valve cusps follow
the coronary arteries as the most common sites of cardiac calcifi-
cations (6,7). Our laboratory has shown that experimental hyper-
cholesterolemia induces an atherosclerotic aortic valve lesion that
expresses bone matrix proteins that are modified by atorvastatin
(8). In the present study, we examined experimental hypercholes-
terolemia with and without atorvastatin in rabbits and character-
ized the mitral valves.
All experiments were performed in accordance with the recom-
mendations of the American Association for the Accreditation of
Laboratory Animal Care (IACUC A282-99). Male New Zealand
white rabbits weighing 2.5 to 3.0 kg were assigned to a control diet
(n  16), 1.0% cholesterol-fed diet (n  16), or cholesterol- and
atorvastatin-fed diet (n  16) for eight weeks. Cholesterol-fed
animals received a diet supplemented with 1.0% cholesterol (wt/
wt; Purina Mills, Woodmont, Indiana), and the cholesterol- and
atorvastatin-fed group was given atorvastatin at 2.5 mg/kg/day.
Lipid levels were obtained. The mitral valves were harvested and
embedded in paraffin and stored at 80°C for RNA analysis.
Immunohistochemistry was performed for the atherosclerotic
markers alpha-actin, proliferating cell nuclear antigen, and mac-
rophage (RAM11). Semiquantitative reverse-transcription poly-
merase chain reaction for osteopontin (OP) was performed. All
experimental studies were performed as described previously (8).
The samples were scored semiquantitatively by two observers who
were blinded to the treatment arms, and the results were expressed
qualitatively and demonstrated in the photomicrographs. No
systematic differences existed between readers in the grading of
stains by paired t tests (p  0.33). The kappa value for agreement
between readers was 0.58, indicating moderate agreement. Com-
parison was made among the three groups using analysis of
variance. The Scheffe method of adjustment was performed for
multiple pairwise comparisons. All statistical tests were two-tailed,
and p  0.05 was considered significant. The data are reported as
the mean and the standard error of the mean.
The normal mitral valve in Figure 1, panel A1 shows a thin, intact
valve attached to the papillary muscle as demonstrated by the
alpha-actin immunostain. Furthermore, there was no evidence of
foam cell formation (Fig. 1, B1), cellular proliferation (Fig. 1, C1),
calcification shown byMasson trichrome staining (Fig. 1, D1), or OP
deposition (Fig. 1, E1). However, mitral valves from the hypercho-
lesterolemic showed a considerable increase in connective tissue and
collagen formation (Fig. 1, D2). Likewise, there were focal areas of
increased myofibroblast proliferating cell nuclear antigen staining and
alpha-actin–positive staining cells (Fig. 1, A2 and C2), as well as areas
staining positive for macrophages (RAM11), suggesting foam cell
infiltration (Fig. 1, B2). Finally, there was significant deposition of
OP within the mitral valve leaflet, which was not observed in the
controls (Fig. 1, E2). Figure 1, panels A3 to E3 demonstrate the
effects of the atorvastatin on the mitral valve for all of these treatments
with marked improvement in the atherosclerotic lesion. We further
confirmed the OP RNA expression in Figure 2A. There were
significantly increased levels of OP RNA gene expression in the
hypercholesterolemic animals compared with either the control or
atorvastatin-treated animals. Figure 2B, demonstrates significant de-
creases in the amount of all the immunohistochemical markers with
atorvastatin treatment.
It is evident from this experimental model that mitral valve
calcification represent an active, complex process involving myofi-
broblast proliferation and osteoblast bone matrix protein expres-
sion and that this process may be modified by atorvastatin. There
have been numerous studies that correlate MAC and atheroscle-
rotic disease. The clinical significance of MAC includes increased
development of aortic atheromas, stroke, and peripheral vascular
disease (9–11). These findings suggest that MAC should be added
to other conventional risk factors for predicting coronary artery
disease, as it may indicate a generalized atherosclerotic process
within the valves and vasculature. The appearance of mitral valve
calcifications may indicate a generalized atherosclerotic process
and be predictive of coronary artery disease, suggesting that it
should be included with other risk factors for coronary artery
disease. Atorvastatin treatment reduces the cellular proliferation
and early bone matrix expression, which may have implications for
future treatment of patients in the early stages of MAC. The
limitation of this study is the effect demonstrated in this study was
found throughout the valve leaflet, including the mitral annulus.
Future studies, including longer duration of cholesterol diet, are
needed to demonstrate calcification in the future.
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Figure 2. Reverse transcription polymerase chain reaction (RT-PCR) and
quantification data. (A) RT-PCR using the total ribonucleic acid (RNA)
from the aortic valves for osteopontin (330 bp) results normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (451 bp). (B)
Quantification results for cholesterol levels, RAM-11, alpha-actin, os-
teopontin, proliferating cell nuclear antigen (PCNA), and osteopontin
RNA results. **p  0.001 compared with control; *p  0.001 compared
with high-cholesterol diet.
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Letters to the Editor
Cardiac Resynchronization Therapy,
Central Sleep Apnea, and Cheyne-Stokes
Respiration in Chronic Heart Failure Patients
We congratulate Sinha et al. (1) for their interesting and innova-
tive report in JACC on the therapeutic effect of biventricular pacing
on central sleep apnea (CSA). A few questions remain: the title
suggests some information about Cheyne-Stokes respiration
(CSR), which is not equivalent to CSA; however, results are
lacking. Were all apnea/hypopnea events central in nature or did
some also have obstructive or mixed events? Completely blinded
serial scoring is difficult in patients undergoing an intervention
such as an implantation device, and therefore a bias in visual
scoring might be possible. We would be interested in learning
some additional objective values such as desaturation index or time
in apnea. This would be of greater value than minimum SaO2 in
their Table 3.
In their discussion, the investigators state that CSA is related to
heart failure, a statement that contrasts to similar findings on
exercise and echocardiography in both groups. In view of this, how
do the researchers explain the dramatic effects of cardiac resyn-
chronization therapy (CRT) on CSA when the benefit of CRT (on
echocardiography and exercise) is equal in patients with and
without CSA? Moreover, the effect of CRT on sleep apnea, as
described by Sinha et al. (1), is huge and much higher than in our
experience and even higher than after cardiac transplantation (2,3).
In these reports, cyclic respiration/CSR was abolished, but sleep
apnea persisted or got worse in a considerable number of patients.
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REPLY
We thank Dr. Scharf and colleagues for their valuable comments
to our study on central sleep apnea (CSA) and cardiac resynchro-
nization therapy (CRT) (1). Importantly, all patients in our study
had CSA and no evidence of obstructive sleep apnea (OSA).
Because apnea occurred with a periodic pattern in patients with
known advanced heart failure we believe that the breathing pattern
can be classified as CSA although timing of arousals relative to
respiratory events could not be evaluated with the polygraphy
system used. We agree that desaturation index, breathing cycle
length, and time in apnea add important information and have
summarized these data in Table 1.
We have now studied more patients with mixed apnea or OSA
and found less improvement in mixed apnea and no significant
effect in OSA (2). Therefore, we believe that CRT works mainly
on CSA by improving cardiac hemodynamics.
The notion that CSA is related to the severity of heart failure
was derived from previous studies (3) and not from our data. We
caution that our results refer to a small group of patients with short
Table 1. Additional Parameters Obtained by Polygraphy Before
and During CRT
Pre-CRT On CRT p Value
Desaturation index 23  10.6 9.6  5 0.002
Cycle length (s) 60.6  5.7 45.8  2.2 0.002
Ventilation/apnea length
ratio
1.15  0.12 0.42  0.1 0.001
CRT  cardiac resynchronization therapy.
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